Intensive Bevacizumab Boosts Vision in Macular Degeneration
METHODOLOGY:
Researchers evaluated the long-term outcomes of anti-VEGF therapy for neovascular AMD in the Netherlands — where bevacizumab is the mandated first-line drug — to assess if improvements in vision were superior to those in socioeconomically similar countries using ranibizumab or aflibercept.
They analyzed 5-year data from the Fight Retinal Blindness! registry, comparing outcomes for 1473 eyes in 1229 patients treated with bevacizumab (Dutch cohort) with those for 7144 eyes in 5884 patients receiving aflibercept or ranibizumab (reference cohort).
Patients enrolled in the registry after January 1, 2016, with at least 6 months of follow-up and no prior history of treatment with an anti-VEGF agent were included in the analysis.
Primary outcome measures were mean visual acuity at yearly intervals until 60 months, and secondary outcomes included injection frequency and rates of switching to alternative anti-VEGF agents.
TAKEAWAY:
At 60 months, mean visual acuity among patients in the Dutch cohort was 2.3 letters higher than that of patients in reference cohort; eyes with poor baseline vision in the Dutch cohort showed sustained improvements through month 60, whereas their counterparts in the reference cohort regressed to poor vision within 3 years.
Patients in the Dutch cohort received 14.5 more injections over 5 years than those in the reference cohort, indicating a more aggressive treatment approach.
At 60 months, the Dutch cohort also showed higher rates of switching to alternative anti-VEGF agents than the reference cohort (70.9% vs 51.9%), with a shorter median time to switching (11.9 vs 17.7 months), suggesting ophthalmologists in the Netherlands were quicker to change therapy when patients exhibited a poor response to treatment.
IN PRACTICE:
'There is little evidence to suggest that the higher visual outcomes for the Dutch group are due to the choice of drug as bevacizumab has not been shown to be superior to other anti-VEGF drugs,' the researchers wrote. 'The head-to-head trials against ranibizumab, IVAN and CATT, only demonstrated that bevacizumab was not inferior. The higher visual gain is likely to result from a more aggressive injection frequency' as well as a higher visual acuity at baseline.
SOURCE:
The study was led by H. Mhmud and J. P. Vermeulen, of the Department of Ophthalmology at Erasmus Medical Center in Rotterdam, the Netherlands. It was published online on June 15, 2025, in Ophthalmology and Therapy .
LIMITATIONS:
A key limitation noted by the researchers was the lack of information about specific treatment regimens used. Decisions about treatment were made by the individual clinicians, and little is known about the reason behind their choices. Reasons for loss to follow-up were recorded for less than 20% of patients.
DISCLOSURES:
This study did not receive any funding. The authors declared having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Children more likely to engage with junk food posts from influencers
Children and teenagers are being bombarded with videos and pictures of unhealthy food online, polling suggests, with youngsters more likely to engage with content about junk food if it is shared by influencers. Cancer Research UK said that ministers must do more to protect young people from 'harmful marketing that could increase their risk of obesity and cancer in the future'. New laws, which come into force next year, will end paid-for advertising, including online, of specific foods which are high in fat, sugar and salt. The charity said that it is important for the implementation of the legislation to go ahead as planned after repeated delays. And it warned that not all exposure to junk food will end when the new laws come into place as there will still be online advertising loopholes. The charity surveyed 4,000 children and young people aged 11 to 21 across the UK and found: – Half (52%) saw unhealthy food and drink products from either businesses or influencers on social media in the last month. – Almost four in 10 (39%) said they engaged with these posts by commenting, liking or sharing. – They were more likely to interact with a post from an influencer compared to a business. Some reported that seeing content about food high in fat, salt and sugar made them feel tempted or hungry. 'A giant cookie bowl keeps showing up, when I see it, I feel like ordering a dessert and I feel really hungry,' an 11 year-old told the charity. A 15-year-old said: 'I'd say at least every two minutes that I'm on Instagram I'd see at least one food-related post.' Liv Cheek, prevention policy manager at Cancer Research UK, said: 'Being overweight or obese is the second biggest cause of cancer in the UK after smoking, and rates among young people are rising. 'Our survey shows more than half of young people regularly see unhealthy food and drink content online, often promoted by influencers. 'Advertising can shape what children eat, so the UK Government must help create an online environment that empowers, rather than undermines, healthy changes. 'Planned restrictions on junk food advertising online are a vital step to protect young people's health. 'However, these measures must be properly enforced and strengthened by closing any remaining gaps in the online marketing rules. 'We urge the UK Government and regulators to take bold action to shield young people from harmful marketing that could increase their risk of obesity and cancer in the future.' Next month, experts will meet at the The International Food Addiction and Comorbidities Conference in London to discuss growing health concerns about food addiction. The Daily Express reported organisers believe that some 10 million people in the UK are hooked on junk food including pizza, chocolate, crisps, biscuits and ice cream. A Government spokesperson said: 'Obesity robs children of the best start in life and sets them up for a lifetime of health problems, which costs the NHS billions. 'The junk food advertising restrictions on TV and online are a crucial part of our Plan for Change to raise the healthiest generation of children ever. 'By reducing children's exposure to junk food advertising, we will remove up to 7.2 billion calories from UK children's diets each year and deliver around £2 billion in health benefits.'
Yahoo
3 hours ago
- Yahoo
Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline
Merck KGaA (NYSE:MRK) is going back on offense in neurologyand it's betting big. The German drugmaker just announced a collaboration with Skyhawk Therapeutics that could top $2 billion, aimed at developing RNA-targeting small molecules for hard-to-treat neurological diseases. Under the deal, Skyhawk will lead discovery and preclinical development using its proprietary RNA splicing tech, while Merck steps in if the science clears early hurdles. Though financial terms weren't disclosed, the structure includes upfront and milestone payments, plus royalties tied to future sales. Warning! GuruFocus has detected 2 Warning Sign with MRK. This isn't a pivot. It's a rebuild. After two major clinical failures rocked its pipeline and with its blockbuster multiple sclerosis drug Mavenclad losing exclusivity starting in 2026, Merck is under pressure to restock its innovation shelf. CEO Belen Garijo is tightening focus on external innovationand fast. That includes this Skyhawk deal, and the recently closed acquisition of SpringWorks Therapeutics, which is expected to start contributing to Merck's healthcare revenue in the second half of this year. Behind the scenes, this deal speaks volumes about where Merck thinks the next frontier lies. Amy Kao, who heads neuroscience and immunology research at Merck, called RNA splicing modulation an exciting frontierand that might be understating it. The company is betting that Skyhawk's tech could unlock new treatments where traditional approaches have failed. If even one program makes it through to commercialization, it could mark a turning point in Merck's quest to reignite long-term growth in its pharma arm. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Your morning coffee is putting pep in your step — and making you happier too
That cup of morning joe is actually lifting your spirits. People who regularly consume the hot bean juice or another caffeinated beverage are usually in a better mood after drinking it, according to European researchers. 'Caffeine works by blocking adenosine receptors, which can increase dopamine activity in key brain regions — an effect that studies have linked to improved mood and greater alertness,' England-based University of Warwick's Professor Anu Realo explained in a statement. Essentially, the effects of adenosine, which is a naturally occurring compound that helps to regulate the heart and sleep cycles, are reduced. People feel more awake and energetic. This mood boost was found to be more pronounced in the morning than later in the day. Although, notably, it is unclear if these findings are related to a reduction in withdrawal symptoms following sleep. 'Even people with moderate caffeine consumption can experience mild withdrawal symptoms that disappear with the first cup of coffee or tea in the morning,' noted Realo. Still, regardless of peoples' level of consumption, the observed effect was the same: a happier and more enthusiastic mood on mornings with caffeine. The researchers had believed this outcome could vary for each of the 236 young German adults they studied over the course of a month. They expected that people with higher levels of anxiety would experience negative mood changes after drinking caffeine. Participants' mood was tracked using short questionnaires given to them on their smartphones seven times a day, asking about their current mood and whether they had consumed a caffeinated drink within the prior 90 minutes. 'We were somewhat surprised to find no differences between individuals with varying levels of caffeine consumption or differing degrees of depressive symptoms, anxiety, or sleep problems,' Justin Hachenberger, from Germany's Bielefeld University, said. 'The links between caffeine intake and positive or negative emotions were fairly consistent across all groups.' While there were also links to negative moods observed, the researchers said the effects were less pronounced after drinking coffee than on days without it — and this effect was not dependent on the time of day. The study authors cautioned that caffeine can lead to dependence. Excessive intake is linked to various health risks, including an increased heart rate, anxiety, and digestive issues. Consuming it later in the day can lead to sleep problems. Ultimately, however, the findings could have wide-ranging implications for caffeine drinkers around the world. About 80 percent of adults around the world consume caffeinated beverages, according to Bielefeld's Professor Sakari Lemola. Previous research has shown that caffeine could help people with depression and even reduce the risk of suicide. 'We identify caffeine as the most likely candidate of any putative protective effect of coffee,' Michel Lucas, research fellow at the Harvard School of Public Health, said in 2013. The findings were published in the journal Scientific Reports. If you are based in the U.S., and you or someone you know needs mental health assistance right now, call or text 988, or visit to access online chat from the 988 Suicide and Crisis Lifeline. This is a free, confidential crisis hotline that is available to everyone 24 hours a day, seven days a week. If you are in another country, you can go to to find a helpline near you.
